Filing Flows › Health Care › Sanara MedTech (SMTI)
Sanara MedTech (SMTI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Sanara MedTech (SMTI) Q2 2026 earnings results →
Q2 2026 Revenue up 9% year over year to $28.1M · 2¢ of every $1 of revenue lost · operating margin 6.3%
Sanara MedTech made $28.1M in Q2 2026 (+9% Y/Y): Soft Tissue Repair Products $25.2M, Bone Fusion Products $2.9M. Operating margin 6.3%, net loss $453K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $28.1M in Q2 2026, up 9% year over year and up 1% from the previous quarter. Soft Tissue Repair Products was the largest line at 90% of revenue. Soft Tissue Repair Products added $2.6M year over year (up 11%), 111% of the total change. Bone Fusion Products declined 8%.
Gross margin was 93.0%, up 0.5 points from Q2 2025. Operating profit was $1.8M, a 6.3% margin (down 3.3 points year over year). Operating profit fell $707K even though revenue rose $2.3M versus Q2 2025, so costs grew faster than sales. Operating expenses grew 14% against revenue growth of 9%. The fastest-growing cost line was General & admin (+45%). The quarter ended with a net loss of $453K, after a profit of $459K the previous quarter. Net interest and other expense of $2.2M was the main reason.
Operating cash flow was $2.0M (down 23% year over year). Non-cash charges added back $619K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $376K. Capital expenditures of $5K left free cash flow of $2.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $28.1M | +9% | 6.3% | −$453K | $2.0M |
| Q1 2026 | 10-Q | May 12, 2026 | $27.8M | +19% | 9.5% | $459K | −$2.5M |
| Q4 2025 | 10-K | Mar 24, 2026 | $27.5M | +5% | 3.8% | −$1.6M | $3.9M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $26.3M | +22% | 11.2% | −$30.4M | $2.2M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $25.8M | +28% | -0.1% | −$2.0M | $2.7M |
| Q1 2025 | 10-Q | May 14, 2025 | $23.4M | +26% | -8.9% | −$3.5M | −$2.0M |
| Q4 2024 | 10-K | Mar 25, 2025 | $26.3M | +49% | -1.4% | −$1.7M | $932K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Sanara MedTech
We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. Our products are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for healthcare systems. We strive to be one of the most innovative and comprehensive providers of effective surgical solutions and are continually seeking to expand our offerings for patients requiring surgical treatments in the United States.
In its own words, from its 10-K, filed Mar 24, 2026.
Sanara MedTech against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +9%. Operating margin: 6.3% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SMTI Sanara MedTech | Q2 2026 | $28.1M | +9% | 6.3% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Sanara MedTech 10-Q on SEC EDGAR · CIK 714256 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
13F: who owns SMTI and who is buying
More on SMTI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results